These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 18316001)

  • 1. Effects of antidiabetic and antihyperlipidemic agents on C-reactive protein.
    Dandona P
    Mayo Clin Proc; 2008 Mar; 83(3):333-42. PubMed ID: 18316001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-sensitivity C-reactive protein: a novel cardiovascular risk predictor in type 2 diabetics with normal lipid profile.
    Asegaonkar SB; Marathe A; Tekade ML; Cherekar L; Bavikar J; Bardapurkar J; Ajay R
    J Diabetes Complications; 2011; 25(6):368-70. PubMed ID: 22055258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
    Li JJ; Fang CH
    Med Hypotheses; 2004; 62(4):499-506. PubMed ID: 15050096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
    Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
    Am J Cardiol; 2006 Mar; 97(5):646-50. PubMed ID: 16490430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones.
    Nesto R
    Diabet Med; 2004 Aug; 21(8):810-7. PubMed ID: 15270782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-reactive protein (CRP)-lowering agents.
    Prasad K
    Cardiovasc Drug Rev; 2006; 24(1):33-50. PubMed ID: 16939632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander?
    Nordestgaard BG; Zacho J
    Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):521-4. PubMed ID: 19695857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anti-inflammatory effects of exercise training in patients with type 2 diabetes mellitus.
    Kadoglou NP; Iliadis F; Angelopoulou N; Perrea D; Ampatzidis G; Liapis CD; Alevizos M
    Eur J Cardiovasc Prev Rehabil; 2007 Dec; 14(6):837-43. PubMed ID: 18043308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
    Tandon N; Ali MK; Narayan KM
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes.
    Ovalle F
    Clin Ther; 2011 Apr; 33(4):393-407. PubMed ID: 21635987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Impact of antidiabetic therapy on the risk of cardiovascular diseases and their complications in patients with type 2 diabetes mellitus].
    Ametov AS; P'ianykh OP; Chernikova NA
    Ter Arkh; 2010; 82(8):71-5. PubMed ID: 20873250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature.
    Patrick L; Uzick M
    Altern Med Rev; 2001 Jun; 6(3):248-71. PubMed ID: 11410071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prevention of cardiovascular disease in type 2 diabetic patients].
    Yokota C
    Nihon Rinsho; 2003 Jul; 61(7):1161-6. PubMed ID: 12877078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A primary care register for impaired glucose handling (IGH): impact on cardiometabolic profile.
    Heald AH; Knapman H; Nair S; Chambers T; Radford D; Rushton T; Anderson SG
    Prim Care Diabetes; 2012 Oct; 6(3):213-9. PubMed ID: 22560663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High plasma C-reactive protein (CRP) is related to low paraoxonase-I (PON-I) activity independently of high leptin and low adiponectin in type 2 diabetes mellitus.
    Dullaart RP; de Vries R; Sluiter WJ; Voorbij HA
    Clin Endocrinol (Oxf); 2009 Feb; 70(2):221-6. PubMed ID: 18505467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
    Cavender MA; Lincoff AM
    Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistin - concentrations in persons with type 2 diabetes mellitus and in individuals with acute inflammatory disease.
    Stejskal D; Adamovská S; Bartek J; Juráková R; Prosková J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2003 Nov; 147(1):63-9. PubMed ID: 15034607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetes mellitus: a cardiovascular disease.
    Candido R; Srivastava P; Cooper ME; Burrell LM
    Curr Opin Investig Drugs; 2003 Sep; 4(9):1088-94. PubMed ID: 14582453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-reactive protein is a strong independent predictor of death in type 2 diabetes: association with multiple facets of the metabolic syndrome.
    Linnemann B; Voigt W; Nobel W; Janka HU
    Exp Clin Endocrinol Diabetes; 2006 Mar; 114(3):127-34. PubMed ID: 16636979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of hypoglycemic agents on mortality and major cardiovascular outcomes in patients with type 2 diabetes mellitus: a narrative review [88].
    Miranda VP; Rodrigues MJ; Gonçalves FR; Nunes JP
    Rev Port Cardiol; 2009 Oct; 28(10):1099-119. PubMed ID: 20058777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.